The Global PARP Inhibitor Biomarkers Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 8.3% CAGR during the forecast period.
North America boasts advanced healthcare infrastructure, including well-established clinical laboratories, oncology centres, and research institutions. Thus, the North America region acquired 42.5% revenue share in the market 2023. The availability of diagnostic technologies and skilled healthcare professionals enhances the accessibility and utilization of biomarker testing services, driving the demand for it in North America.
Oncology research is continually uncovering new biomarkers associated with cancer development, progression, and response to therapy. As our understanding of the molecular pathways underlying cancer improves, researchers are identifying biomarkers that predict response to specific treatments, including it.
Additionally, point-of-care testing brings diagnostic capabilities closer to the patient, enabling biomarker testing to be performed outside traditional laboratory settings, such as outpatient clinics, physician offices, or even the patient’s home. Hence, the expansion of point-of-care testing is raising the market’s growth.
However, Biomarker testing often involves sophisticated laboratory techniques and specialized equipment, which can be expensive to procure and maintain. Additionally, the cost of reagents, consumables, and personnel required for biomarker testing adds to the overall expense. In conclusion, the high cost of biomarker testing hinders the market’s growth.
Economic hardships and changes in healthcare priorities during the pandemic affected patient access to cancer treatments, including this. Financial constraints, job losses, and changes in insurance coverage may have influenced treatment decisions and patient adherence. Thus, the COVID-19 pandemic had a negative impact on the market.
North America boasts advanced healthcare infrastructure, including well-established clinical laboratories, oncology centres, and research institutions. Thus, the North America region acquired 42.5% revenue share in the market 2023. The availability of diagnostic technologies and skilled healthcare professionals enhances the accessibility and utilization of biomarker testing services, driving the demand for it in North America.
Oncology research is continually uncovering new biomarkers associated with cancer development, progression, and response to therapy. As our understanding of the molecular pathways underlying cancer improves, researchers are identifying biomarkers that predict response to specific treatments, including it.
Additionally, point-of-care testing brings diagnostic capabilities closer to the patient, enabling biomarker testing to be performed outside traditional laboratory settings, such as outpatient clinics, physician offices, or even the patient’s home. Hence, the expansion of point-of-care testing is raising the market’s growth.
However, Biomarker testing often involves sophisticated laboratory techniques and specialized equipment, which can be expensive to procure and maintain. Additionally, the cost of reagents, consumables, and personnel required for biomarker testing adds to the overall expense. In conclusion, the high cost of biomarker testing hinders the market’s growth.
Economic hardships and changes in healthcare priorities during the pandemic affected patient access to cancer treatments, including this. Financial constraints, job losses, and changes in insurance coverage may have influenced treatment decisions and patient adherence. Thus, the COVID-19 pandemic had a negative impact on the market.
Driving and Restraining Factors
Drivers- Growing expansion of oncology research
- Expansion of point-of-care testing
- Increasing prevalence of cancer worldwide
- High cost of biomarker testing
- Complexity of biomarker interpretation
- Growing awareness of biomarker testing
- Increasing development healthcare infrastructure
- Limited availability of targeted therapies
- Increasing competition from alternative therapies
Product Outlook
Based on product, the market is divided into kits and assays. In 2023, the kits segment garnered 63.8% revenue share in the market. Biomarker testing kits offer a user-friendly and convenient solution for healthcare providers to perform biomarker testing in-house without requiring specialized laboratory infrastructure or expertise.Application Outlook
Based on application, the market is categorized into breast cancer, ovarian cancer, and others. The ovarian cancer segment witnessed 30.7% revenue share in the market in 2023. PARP inhibitors have demonstrated clinical efficacy in treating ovarian cancer patients with BRCA mutations. Clinical trials have shown that PARP inhibitors.
Services Outlook
On the basis of services, the market is segmented into BRCA 1 & 2 testing, HRD testing, HRR testing, and others. The BRCA 1 & 2 testing segment recorded 41.8% revenue share in the market in 2023. BRCA1 and BRCA2 mutations are strongly associated with increased sensitivity to this in certain cancers, particularly breast and ovarian cancer.Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 24.4% revenue share in the market. The Asia Pacific region is experiencing a significant increase in the incidence of cancer, including breast, ovarian, and other cancers associated with PARP inhibitor therapy.List of Key Companies Profiled
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Product- Kits
- Assays
- Breast Cancer
- Ovarian Cancer
- Others
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global PARP Inhibitor Biomarkers Market by Product
Chapter 5. Global PARP Inhibitor Biomarkers Market by Application
Chapter 6. Global PARP Inhibitor Biomarkers Market by Services
Chapter 7. Global PARP Inhibitor Biomarkers Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
